Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States

S. M. Bartsch, J. A. McKinnell, L. E. Mueller, L. G. Miller, S. K. Gohil, S. S. Huang, B. Y. Lee

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives The Centers for Disease Control and Prevention considers carbapenem-resistant Enterobacteriaceae (CRE) an urgent public health threat; however, its economic burden is unknown. Methods We developed a CRE clinical and economics outcomes model to determine the cost of CRE infection from the hospital, third-party payer, and societal, perspectives and to evaluate the health and economic burden of CRE to the USA. Results Depending on the infection type, the median cost of a single CRE infection can range from $22 484 to $66 031 for hospitals, $10 440 to $31 621 for third-party payers, and $37 778 to $83 512 for society. An infection incidence of 2.93 per 100 000 population in the USA (9418 infections) would cost hospitals $275 million (95% CR $217–334 million), third-party payers $147 million (95% CR $129–172 million), and society $553 million (95% CR $303–1593 million) with a 25% attributable mortality, and would result in the loss of 8841 (95% CR 5805–12 420) quality-adjusted life years. An incidence of 15 per 100 000 (48 213 infections) would cost hospitals $1.4 billion (95% CR $1.1–1.7 billion), third-party payers $0.8 billion (95% CR $0.6–0.8 billion), and society $2.8 billion (95% CR $1.6–8.2 billion), and result in the loss of 45 261 quality-adjusted life years. Conclusions The cost of CRE is higher than the annual cost of many chronic diseases and of many acute diseases. Costs rise proportionally with the incidence of CRE, increasing by 2.0 times, 3.4 times, and 5.1 times for incidence rates of 6, 10, and 15 per 100 000 persons.

Original languageEnglish (US)
Pages (from-to)48.e9-48.e16
JournalClinical Microbiology and Infection
Volume23
Issue number1
DOIs
StatePublished - Jan 1 2017

Keywords

  • CRE
  • Carbapenem-resistant Enterobacteriaceae
  • Cost
  • Economic burden
  • Model

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States'. Together they form a unique fingerprint.

Cite this